Key trial of Seaside autism drug fails to show benefit
Reuters is reporting that Arbaclofen, a drug that would treat symptoms of social withdrawal, failed to show a benefit in a mid-stage trial. Based on the results Roche Holding AG, has decided to pass on a partnership to develop Arbaclofen. The maker of the drug, Seaside Therapeutics, says it will seek new partners to test the drug further.
No comments:
Post a Comment